GlassScriptPhysician profile
Masha Resman
NPI 1013143890
$9,420.96
in general payments reported to CMS, 2019-2025
40 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $573 · 2021: $1,022 · 2022: $1,325 · 2023: $1,053 · 2024: $3,246 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,184 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,820 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,183.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,820.00 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $2,575.03 | 2019-2025 | Korlym |
| Amgen INC. | $764.00 | 2019-2025 | Tepezza, Evenity, Repatha |
| Novo Nordisk INC | $648.83 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $515.40 | 2020-2025 | |
| Lilly USA, LLC | $497.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Radius Health, INC. | $456.59 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $451.19 | 2021-2023 | Tepezza |
| Abbott Laboratories | $406.74 | 2020-2024 | Freestyle Libre |
| Dexcom, INC. | $333.06 | 2019-2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $303.60 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $297.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $266.41 | 2019-2023 | Belsomra, Januvia, Janumet |
| Insulet Corporation | $228.55 | 2019-2025 | Omnipod |
| Madrigal Pharmaceuticals | $218.21 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $181.24 | 2019-2024 | Licart, Tirosint |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masha Resman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.